NCT06675123View on ClinicalTrials.gov

Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma

PHASE1RecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

November 1, 2025

Primary Completion Date

March 8, 2028

Study Completion Date

March 8, 2028

Conditions
Recurrent Mantle Cell LymphomaRefractory Mantle Cell Lymphoma
Interventions
PROCEDURE

Biopsy

Undergo optional tissue biopsy

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Bone Marrow Aspiration

Undergo bone marrow biopsy and aspiration

PROCEDURE

Bone Marrow Biopsy

Undergo bone marrow biopsy and aspiration

DRUG

BTK Inhibitor

Given BTK inhibitor

PROCEDURE

Computed Tomography

Undergo PET/CT

DRUG

Pacritinib

Given PO

PROCEDURE

Positron Emission Tomography

Undergo PET/CT

Trial Locations (1)

91010

RECRUITING

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER